Published guidance, NICE advice and quality standards

Showing 21 to 30 of 779

Sort by

Published guidance, NICE advice and quality standards
Title	Reference number	Published	Last updated
Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments	TA947	31 January 2024	31 January 2024
Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments	TA948	31 January 2024	31 January 2024
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal)	TA945	30 January 2024	30 January 2024
Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer	TA946	17 January 2024	17 January 2024
Sebelipase alfa for treating Wolman disease	HST30	10 January 2024	10 January 2024
Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer	TA944	10 January 2024	10 January 2024
Targeted-release budesonide for treating primary IgA nephropathy	TA937	20 December 2023	20 December 2023
Ravulizumab for treating generalised myasthenia gravis (terminated appraisal)	TA940	20 December 2023	20 December 2023
Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal)	TA941	20 December 2023	20 December 2023
Empagliflozin for treating chronic kidney disease	TA942	20 December 2023	20 December 2023